I-Vipidia iyisidakamizwa esenzelwe ukwelashwa kwesifo sikashukela sohlobo olungayekeleli i-insulin.
Umuthi usetshenziswa zombili ekwenziweni kwe-monotherapy, nasekwelashweni okuyinkimbinkimbi kwalesi sifo njengengxenye yokwelashwa kwezidakamizwa.
I-Alogliptin uhlobo olusha lwesidakamizwa olusetshenziswa ekwelapheni isifo sikashukela, esinganciki ku-insulin. Imithi yalolu hlobo ingeyeqembu lezidakamizwa elibizwa ngokuthi i-incretinomimetics.
Leli qembu lifaka i-glucagon-efana ne-glucose-insulinotropic polypeptides. Lezi zingxube ziyaphendula ekungeneni komuntu ngokuvuselela ukwakheka kwe-insulin ye-hormone.
Eqenjini kunama-subgroups ama-2 we-incretin mimetics:
- Izinto ezihlanganisiwe ezinesenzo esifana nesenzo sama-incretins. Izakhi ezinjalo zamakhemikhali zifaka i-liraglutide, exenatide ne-lixisenatide.
- Amakhompiyutha akwazi ukwelula isenzo sama-incretin adalwe emzimbeni. Ukwelulwa kwesenzo se-incretin kwenzeka ngenxa yokuncipha kokukhiqizwa kwe-enzyme ekhethekile, i-dipeptidyl peptidase-4, eqhuba ukubhujiswa kwama-incretin. Izingxube ezinjalo zifaka i-sitagliptin, i-vildagliptin, i-saxagliptin, i-linagliptin ne-alogliptin.
I-Alogliptin inethonya elinamandla lokukhetha i-inhibitory ku-peptidase-4 ekhethekile ye-enzyme. Umphumela we-inhibitory wokukhetha we-enzyme DPP-4 ku-alogliptin uphakeme kakhulu uma uqhathaniswa nomphumela ofanayo kuma-enzymes ahlobene.
I-Vipidia ingagcinwa iminyaka emithathu. Ngemuva kwalesi sikhathi, ukusetshenziswa komuthi kwenqatshelwe. Indawo yokubeka umuthi kufanele ivikeleke ekuchayweni kwelanga. Futhi izinga lokushisa endaweni yokubeka akufanele libe ngaphezu kwama-25 degrees.
Izinkomba kanye ne-contraindication ukuze zisetshenziswe
I-Vipidia ing umuthi we-hypoglycemic womlomo. Leli thuluzi lisetshenziswa ekwelapheni isifo sikashukela sohlobo 2. Lesi sidakamizwa sikashukela sisiza ukuthuthukisa ukuphathwa kwe-glycemia ku-plasma yegazi lomuntu ogulayo. Kusetshenziswa umuthi lapho ukusetshenziswa kwendlela yokudla nokuzivocavoca okulinganiselayo kunganikezi imiphumela oyifunayo.
Umuthi ungasetjenziswa njengewukuphela kwesakhi ngesikhathi se-monotherapy. Ngaphezu kwalokho, i-Vipidia ingasetshenziswa ngokuhambisana nezinye izidakamizwa ze-hypoglycemic ekwelapheni uhlobo 2 lwesifo sikashukela ngendlela yokwelapha okuyinkimbinkimbi.
Umuthi ungasetshenziswa ekwelapheni ushukela ngokuhambisana ne-insulin.
Njenganoma yimuphi umuthi, i-Vipidia inezindlela eziningi zokukhwabanisa ezikhawula ukusetshenziswa komuthi. I-contraindication esemqoka yilena elandelayo:
- ukuba khona kwesifo sikashukela sohlobo 2 kwisiguli, i-hypersensitivity to alogliptin kanye nezingxenye ezisizayo zomuthi;
- isiguli sinesifo sikashukela ngendlela esekela i-insulin;
- Ukukhonjwa kwezimpawu ze-ketoacidosis ezikhula emzimbeni wesiguli ngokumelene nesizinda sikashukela;
- ukukhonjwa kokwehluleka kwenhliziyo okukhulu;
- ukuphazamiseka kwesibindi, okuhambisana nokuvela kokulimazeka kokusebenza;
- ukuthuthukiswa kwe-pathologies enzima yezinso, ehambisana nokuvela kokungasebenzi kahle kokusebenza;
- isikhathi sokuzala ingane;
- inkathi yokuhlanza;
- iminyaka yesiguli ingafika eminyakeni eyi-18.
Ukuqapha kufanele kuthathwe lapho isiguli sine-pancreatitis kanye nokuqina okulinganiselwe kwe-renal ephazamisekile nokusebenza kwe-hepatic.
Ngaphezu kwalokho, kufanele kuqashelwe lapho usebenzisa umuthi njengengxenye ekwelapheni okunesifo sikashukela sohlobo II.
Imiyalo yokusebenzisa umuthi
Umuthi uphuzwa ngomlomo. Imvamisa, umthamo wokwelapha onconyelwe ukusetshenziswa ngu-25 mg.
Umthamo onembe ngokwengeziwe wokusebenzisa umuthi unqunywa udokotela oholayo ebheka imiphumela etholwe ngesikhathi kuhlolwa umzimba wesiguli kanye nezimpawu zayo.
Umuthi uthathwa kanye ngosuku, umuthi uthathwa ngokungakhathalekile uhlelo lokudla. Ukuthatha umuthi kuhambisana nokuphuza amanzi amaningi.
Ukusetshenziswa kwomuthi kungenzeka kulezi zimo ezilandelayo:
- Njengomuthi we-monotherapy wohlobo 2 sikashukela mellitus.
- Ekusetshenzisweni kokwelashwa okuyinkimbinkimbi kwalesi sifo, njengengxenye yokwelapha okunjalo. Ngokubambisana ne-vipidia, metformin, i-sulfonylurea derivatives noma i-insulin ingathathwa.
Endabeni ye-Vipidia ehlanganiswe neMetformin, ukulungiswa komthamo womuthi akudingeki. Ukulungiswa kwedosi kuyadingeka lapho usebenzisa umuthi ngokuhlangana nezidakamizwa ezitholakala ku-sulfonylurea noma i-insulin.
Umthamo uguqulwa ukuze uvikele ukuqala kwesimo se-hypoglycemic esigulini esinesifo sikashukela mellitus.
Ukuqapha kufanele kuqiniswe uma usebenzisa i-Vipidia ngokuhlangana neMetformin Teva ne-thiazolidinedione ekwelapheni isifo sikashukela.
Lapho kuvela izimpawu zokuqala ze-hypoglycemia, umthamo weMetformin ne-thiazolidinedione kufanele uncishiswe.
Lapho uthatha i-Vipidia, imiphumela emibi elandelayo ingenzeka:
- kusuka ohlelweni lwezinzwa, ukuvela kwekhanda elijwayelekile;
- kusuka emgudwini wesisu, ukubonakala kobuhlungu esiswini, kuphonsa okuqukethwe esiswini emgodini wesibeletho, ukuthuthukiswa kwezimpawu ze-pancreatitis eyingozi;
- kusuka ohlelweni lwe-hepatobiliary, ukuvela kweziphazamiso emsebenzini wesibindi kungenzeka;
- ukungezwani komzimba kungavela ngendlela yokulunywa, imishayo, i-edema kaQuincke;
- ukuvuvukala kwe-mucosa yamakhala ne-pharynx kungenzeka;
Ngaphezu kwalokho, amasosha omzimba angadala imiphumela emibi, ekhonjiswe ngendlela ye-anaphylaxis.
Izindleko ze-Vipidia nezimpawu zayo
Ukusetshenziswa kwamacwecwe e-Vipidia kwisifo sikashukela kuvame ukuba okuhle.
Uma sahlulela umuthi ngokubuyekezwa ukuthi abantu abasebenzisa i-Vipidia bashiya ngakho, singaphetha ngokuthi umuthi ungumuthi osebenza kakhulu ongalawula kahle izinga le-glycemia emzimbeni womuntu onesifo sikashukela sohlobo 2.
Imithi isithako esisebenzayo, okuyi-alogliptin kuze kube manje, ngaphezu kweVipidia ayibhalisiwe.
Izidakamizwa ezithuthukisiwe, izakhi ezisebenzayo zazo eziyinkimbinkimbi zeqembu incretinomimetics.
Imithi ejwayelekile kakhulu eyi-analogues yeVipidia yile elandelayo:
- UJanuvia umuthi we-hypoglycemic owenziwe ngesisekelo se-sitagliptin. Ukukhishwa komuthi kusimo samaphilisi aqukethe i-25, 50 ne-100 mg yento esebenzayo. Izinkomba zokusetshenziswa kweJanuvia ziyefana nalezo uVapidia anazo. Umuthi lo ungasetjenziswa nge-monotherapy nofana nangomuthi oyinkimbinkimbi.
- I-Yanumet ilungiselelo eliyinkimbinkimbi, eliqukethe i-sitagliptin ne-metformin njengezakhi ezisebenzayo. Umthamo wengxenye yokuqala esebenzayo ngu-50 mg, kuthi i-metformin ekwakhiweni komuthi ingaqukethelwa ngamanani ahlukahlukene. Umuthi uyatholakala ngezinhlobo ezintathu - 50, 850 no-1000 mg.
- IGalvus njengengxenye esebenzayo iqukethe i-vildagliptin, okuyi-analogue ye-alogliptin. Umthamo wengxenye esebenzayo lapho kulungiswa ngu-50 mg. Umthamo we-metformin ekwakhiweni kwomuthi ngu-500, 850 no-1000 mg.
- I-Onglisa ekwakhekeni kwayo njengezakhi ezisebenzayo iqukethe i-saxagliptin. Le khompiyutha ihlobene nezinto ezihlanganayo ezivimbela i-enzyme depleting incretin. Umuthi uyatholakala kumthamo ka-2,5 no-5 mg.
- I-Combogliz Prolong iyinhlanganisela ye-saxagliptin ene-metformin. Umuthi lo uyatholakala ngesimo sethebhulethi. Ukukhishwa kwezakhi ezisebenzayo kwenzeka ngendlela ebambezelekile.
- I-Trazhenta umuthi we-hypoglycemic owenziwe ngesisekelo se-linagliptin. Ukwakheka kwalo muthi kuqukethe i-5 mg yesakhi esisebenzayo.
Izindleko zesidakamizwa zincike esifundeni lapho isidakamizwa sithengiswa khona eRussia. Intengo ejwayelekile yalesi sidakamizwa ama-ruble angama-843.
Yikuphi okunye ukwelashwa okungasetshenziswa ekwelapheni isifo sikashukela kuchazwe kule vidiyo kulesi sihloko.
